The flow cytometric results showed that the HRMTF NPs could remarkably increase the proportion of the mature DCs (CD11c+CD80+CD86+) both in the primary tumor (39.01%) and in the distant tumor (41.77%) relative to that in the control group (primary tumor: 15.76%; distant tumor: 20.70%) (Fig. S14). This evidence concerns the gene CD86 and neoplasm.